Category: Prohost Letters
End of the Year Decisions ~ Part 3
Prohost Letter #428 End of the Year Decisions ~ Part 3 In Part 3 of this series we selected two firms, both were recently added to the Prohost Portfolio . The first firm, FortySeven (FTSV) , focuses on an immunotherapy...
Read More
February 10, 2019
0
Prohost Letter #439
Prohost Letter #439 The Coronavirus Outbreak - COVID-19 The news announced that the coronavirus (now known as COVID-19 ) outbreak would affect not only people’s health and survival but the world’s economy, Wall Street’s performance, and especially the international giant...
Read More
February 19, 2020
0
Are We Saying Goodbye to Common Sense?
Prohost Letter #441 Biotechnology Companies’ Evaluations Are We Saying Goodbye to Common Sense? The SARS-CoV-2 Vaccines It is said that the difference between the SARS-CoV-2 coronavirus (COVID-19), which is causing the pandemic around the world we are currently suffering from,...
Read More
July 3, 2020
0
The Week in Review #37
From the American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU) Prostate Cancer A presentation by Bayer demonstrated improvement in the treatment of non-metastatic castration-resistant prostate cancer. Separate presentations by Bristol-Myers and Janssen also demonstrated improvement in metastatic castration-resistant...
Read More
February 19, 2019
0
Good news and setbacks during the departed week
The Week in Review #38 SYNOPSIS Good News and Setbacks During the Departed Week from the Prohost Portfolio FIRMS WITH GOOD NEWS SPARK THERAPEUTICS The most important happening, with the most exciting positive impact, has come this time from our...
Read More
March 5, 2019
0
End of the Year Decisions ~ Part 4
Prohost Letter #429 End of the Year Decisions ~ Part 4 We picked for our portfolio what we believed are biotech firms with breakthrough technologies and promising products. The few firms that failed us in the beginning were lacking good...
Read More
March 14, 2019
0
During the Departed Week
The Week in Review #39 During the Departed Week Three Prohost Portfolio Picks Hit Their 52-Week Highs The three picks referred to in the above title are, Novartis (NVS), Array (AARY) and Ionis (IONS) . Previous Prohost Letters discussed Novartis...
Read More
March 19, 2019
0
Stars Before the Coronavirus Outbreak and Those Firms Treating COVID-19
The Week in Review #49 The Stars from the Weeks Preceding the Novel Coronavirus Outbreak Forty Seven Forty Seven ( FTSV ) was added to the Prohost Portfolio on December 21, 2018 at $16.95. In early March, 2020 Forty Seven...
Read More
March 24, 2020
0
Prohost Letter #430
Prohost Letter #430 Rheumatoid Arthritis and Gilead The FINCH 1 trial: Has it reached its primary endpoints? How did the drugs respond as compared to placebo; what is the disability index, clinical remission, disease activity rate and safety results? What’s...
Read More
April 5, 2019
0
The Week in Review #40
Conquering NASH Gilead and Novo Nordisk Conquering NASH What was Gilead Sciences' ( GILD ) announcement at EASL? What is Gilead doing to find effective treatments for NASH? Why would Novo Nordisk's ( NVO ) anti-diabetes GLP-1 receptor drug...
Read More
April 16, 2019
0
Search ProhostBiotech
Popular Links
23andMe Holding Co (ME)Abbott Laboratories (ABT)AbbVie Inc (ABBV)AbCelleraAbeona Therapeutics (ABEO)Ablynx (ABLX)AbVitro IncAcadia (ACAD)Acceleron Pharma (XLRN)AcelRx Pharmaceuticals (ACRX).Acorda Therapeutics Inc (ACOR)Acumen Pharmaceuticals (ABOS)AdaptImmune Therapeutics (ADAP)Adaptive BiotechnologiesADC Therapeutics (ADCT)Adimab LLCAdvanced Micro Devices (AMD)Advaxis (ADXS)Adverum Biotechnologies (ADVM)Aerie Pharmaceuticals (AERI)AgenTus TherapeuticsAgenus (AGEN)AgeX Therapeutics (AGE)Agilent Technologies (A)Agilis Biotherapeutics IncAgios Pharmaceuticals (AGIO)AIM ImmunoTech (AIM)Aimmune Therapeutics (AIMT)Akari Therapeutics (AKTX)Akashi TherapeuticsAkcea Therapeutics (AKCA)Akebia Therapeutics Inc (AKBA)Akero Therapeutics (AKRO)Akous Inc (a wholly owned subsidiary of Eli Lilly Company)Alder BioPharmaceuticals (ALDR)Alexion Pharmaceuticals (ALXN)Alkermes (ALKS)Allergan Plc (AGN)Allogene TherapeuticsAllogene Therapeutics (ALLO)